Fig. 3

Effects of NS1619 and paxilline on the excitability of pyramidal neurons in the ACC following mCCD. a-b, Representative recording traces of the first spike in the neurons from sham and mCCD slices in the presence of paxilline or NS1619 respectively. c, Histograms show the amplitude of fAHP of the first three spikes from the sham group in the absence and presence of paxilline (10 μM) (sham, n = 30, sham+paxilline: n = 10), and from the mCCD group in the absence and presence of NS1619 (10 μM) (mCCD: n = 48, mCCD+NS1619: n = 17).d-f, Histograms show AP duration (d), AP half-width (e) and AP decay time (f) from the sham group in the absence and presence of paxilline (sham: n = 30, sham+paxilline: n = 10), and from the mCCD group in the absence and presence of NS1619 (mCCD: n = 48, mCCD+NS1619: n = 17). ^*p < 0.05, ^**p < 0.01compared with that of mCCD group